U.S. state correlations between oral health metrics and Alzheimer’s disease mortality, prevalence and subjective cognitive decline prevalence

Rana X. Scherer¹ & Warren J. Scherer²

Given the association between periodontal disease (PdD) and Alzheimer’s disease (AD), we examined correlations between states’ age-adjusted AD mortality rates, AD prevalence, subjective cognitive decline (SCD) prevalence, and oral health data. Data sources include the Centers for Disease Control and Prevention, scientific literature, and oral health rankings formulated by WalletHub.com and Toothbrush.org. Pearson (r) or Spearman (rs) correlation coefficients were generated and evaluated. AD mortality rates correlate with dental visits (r = −0.50, p = 0.0003), partial (r = 0.39, p = 0.005) or total (r = 0.44, p = 0.001) edentulism, WalletHub.com (r_s = 0.30, p = 0.03) and Toothbrush.org (r_s = 0.35, p = 0.01) rankings. AD prevalence correlates with dental visits (r = −0.30, p = 0.03), partial (r = 0.55, p = 0.00003) or total (r = 0.46, p = 0.0009) edentulism, prevalence of any (r = 0.38, p = 0.006) or severe-stage (r = 0.46, p = 0.0009) PdD, and WalletHub.com (r_s = 0.38, p = 0.006) rankings. SCD prevalence in adults aged ≥ 45 years correlates with dental visits (r = −0.69, p < 0.00001), partial (r = 0.33, p = 0.02) or total (r = 0.37, p = 0.008) edentulism, prevalence of any (r = 0.53, p = 0.0001) or severe-stage (r = 0.57, p = 0.0002) PdD, WalletHub.com (r_s = 0.53, p = 0.00008) and Toothbrush.org (r_s = 0.60, p < 0.00001) rankings. State metrics indicative of compromised oral health correlate with AD mortality rates, AD prevalence and SCD prevalence.

Recently, evidence has emerged associating periodontal disease (PdD) with the development of, and cognitive decline in, Alzheimer’s disease (AD)¹–⁷. Direct causation has not been definitively established; however, the preponderance of research points to a causative relationship between PdD and AD⁸. This comorbidity is consistent with the “antimicrobial protection hypothesis” of AD pathogenesis⁹–¹¹. The hypothesis asserts that hallmark AD features, including extracellular amyloid-beta (Aβ) plaques, hyper-phosphorylation of tau protein, formation of intracellular neurofibrillary tangles, resultant neuroinflammation and neurodegeneration, are due to host responses to central nervous system (CNS) invasion by pathogens and/or their virulence factors¹¹–¹⁵.

Key to the immune response to CNS infection is Aβ itself. Once thought to be an incidental catabolic byproduct without a normal physiological role, Aβ has been shown to function as an antimicrobial peptide, a component of the innate immune system¹⁶. In the CNS, Aβ binds and disrupts bacterial, viral, and fungal cell membranes, resulting in aggregation and agglutination of pathogenic organisms¹⁷–²². Investigations have shown that Aβ production is induced by exposure to pathogens, their virulence factors and/or chronic neuroinflammation²³–²⁵. Accordingly, Aβ represents an immediate and continued physiological response to invading microorganisms, stimulating chronic neuroinflammation and subsequent compromise of blood–brain-barrier function²⁶–²⁷. Over time, this innate immune response, fueled by continued exposure to bacterial virulence factors, chronic CNS infection, or CNS pathogen reactivation, serves to irreversibly prime microglia to switch into an aggressive, pro-inflammatory state²⁸–³¹.

Consistent with age-dependency of AD development, CNS microglial responses to inflammatory challenge are similarly age-dependent. In young brains, microglial activation is associated with a reparative inflammatory response whereas in aged brains, an exacerbated inflammatory response occurs, resulting in proinflammatory

¹University of Central Florida, The Burnett Honors College, 12778 Aquarius Agora Drive, Orlando, FL 32816-1800, USA. ²St. Luke’s Cataract & Laser Institute, 43309 U.S. Highway 19 N., Tarpon Springs, FL 34689, USA. *email: wjsmd@hotmail.com
microglial priming, neuronal death, synaptic loss, and cognitive decline. Age-related, microglial-associated neurophysiological deficits have also been demonstrated by the inability to generate long-term potentiation, a cellular correlate for learning and memory, in the hippocampus of systemically-inflamed middle-aged, but not young rats. Further supporting the role of microglial dysfunction, rats were observed to have a 96% report that minocycline, an inhibitor of microglial activation, restored long-term potentiation in systemically-inflamed middle-aged rats.

PdD is a nonreversible, chronic, infectious, systemic inflammatory condition characterized by gram-negative polymicrobial dysbiosis of the sub-gingival microbiome. Within the subgingival pocket, colonization by causative organisms such as Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola facilitates biofilm formation and PdD development. The host's exuberant systemic immunologic response to these pathogens results in destruction of gingival connective tissue, resorption of tooth-supporting alveolar bone and tooth loss. Once PdD is established, dental procedures, brushing, flossing, or chewing can induce transient bacteremia, and planktonic dissemination of organisms and their shed outer membrane vesicles to distant organs and tissues, including the heart, liver, brain, coronary and peripheral arteries. Specific to AD, P. gingivalis and its virulence factors, e.g. lipopolysaccharide and gingipains, which are cysteine-proteases associated with bacterial outer membrane and shed membrane vesicles, have been identified in AD brains and in cerebral spinal fluid of suspected AD patients. Furthermore, serum antibody levels against P. gingivalis are increased in AD patients compared to non-AD controls. Repeat episodes of PdD-induced bacteremia provide microorganisms and virulence factors with a hematogenous route to the CNS across a blood–brain barrier compromised by chronic inflammation, or alternatively, direct CNS invasion via the trigeminal nerve or olfactory tract.

SCD is defined as a self-experienced, persistent decline in cognitive capacity relative to a previously normal status. First described in 1982, SCD is one of the earliest detectable risk factors for AD development. Although SCD patients exhibit normal responses to cognitive tasks, functional magnetic resonance imaging studies have revealed aberrant brain activation patterns and compensatory cortical hyperactivation compared to controls. Similar to AD, SCD is associated with CNS Aβ deposition and amyloid status in SCD is predictive of self-perceived cognitive state, current cognition and future cognitive decline.

Studies have confirmed comorbid relationships between AD prevalence, progression and severity, and PdD in select cohorts. In a large cohort, Chen et al. recently discovered that patients with a 10 year history of PdD had a two-fold greater risk of developing AD compared to patients without PdD. Unlike AD, little is known regarding the relationship between PdD and SCD; however, one small study has reported a positive correlation. No previous study has analyzed associations between AD, SCD and PdD on a national level in the U.S. via comparisons of state-specific population data. The present study, utilizing state epidemiological data derived from governmental agencies, and scientific literature, is the first to examine U.S. state relationships between AD, SCD and oral health.

Materials and methods

All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were reviewed and approved by the Office of the Medical Directorate, St. Luke's Cataract & Laser Institute, Tarpon Springs, FL. Because individual patients did not participate as subjects in this research, informed consent was not applicable to the present study. All third party data utilized in this study is available free of charge in the public domain from online databases and government websites (see references for each dataset).

For all 50 U.S. states, age-adjusted AD mortality, age-adjusted AD prevalence, SCD and oral health status data were obtained from several sources. Age-adjusted AD 2016 mortality rates were acquired from the Centers for Disease Control and Prevention (CDC) National Center for Health Statistics website. Estimates of states' age-adjusted AD prevalence were obtained from a study by Koller and Bynam which reviewed records of 4.8 million Medicare beneficiaries across all U.S. states. Age-adjusted AD prevalence rates in adults aged ≥ 45 years were obtained from a study of 227,393 respondents across the U.S. Because CDC oral health data and CDC age-adjusted AD mortality rates were subdivided by gender, a gender-based analysis for these data was also performed. All data used for analysis provided in spreadsheet format in Online Resource 1.

Oral health data reporting percentage of adults visiting a dental clinic and adults > 65 years who have lost all, or ≥6 teeth were acquired from the CDC Oral Health Data by Location which completes 400,000 adult interviews each year. State PdD prevalence rates were obtained from a study by Eke et al. which utilized CDC data from the National Health and Nutrition Examination Survey and Behavioral Risk Factor Surveillance System. Statistics regarding state water fluoridation rates were obtained from the Office of Disease Prevention and Health Promotion.

Data from two national, non-peer-reviewed online state oral health ranking scales developed by WalletHub.com and Toothbrush.org were utilized for comparison to AD and SCD data. The WalletHub.com scale, devised by 7 dental health researchers, evaluated state dental health across two key dimensions, "dental habits and care", and "oral health". These dimensions utilized 26 weighted metrics to generate composite U.S. state oral health scores. The Toothbrush.org ranking system evaluated state oral health status utilizing 20 metrics. Similar to WalletHub.com, the Toothbrush.org state rating system generated composite state oral health rankings based on "dental habits & care" and "oral health". In order to determine whether the WalletHub.com and Toothbrush.org rankings were consistent, a Bland Altman analysis was performed on the ranking data. Upper and lower limits of agreement were calculated by multiplying the standard deviation by (+) or (−) 1.96, respectively.

State-specific age-adjusted AD mortality rates, age-adjusted AD prevalence data and SCD prevalence data were compared to corresponding oral health data to determine whether there existed significant relationships between state AD, SCD and oral health data. Pearson (r) or Spearman rank (τ), correlation coefficients, were calculated and tested (two-tailed) for statistical significance (p-value ≤ 0.05) against the null hypothesis of no correlation, $H_0: \rho = 0$ using a standard table of critical values for r. Ranked data from WalletHub.com and Toothbrush.
A corresponding p-value ≤ 0.05 indicates that the data set is not normally distributed. The Kolmogorov–Smirnov test statistic (D) was calculated for each data set to determine whether it is normally distributed. The age-adjusted AD mortality rates (D = 0.086) were evaluated using Spearman rank correlation coefficients. Microsoft Excel was used to calculate correlation coefficients and generate scatter plots.

It has been reported by some authors that the Pearson correlation is robust and can withstand violations of assumptions such as normality whereas others state that highly non-normal data distributions can reduce r values and inflate Type I error rates\(^5\). Given that non-normal data distributions could potentially affect r, a Kolmogorov–Smirnov test statistic (D) was calculated for each data set to determine whether it is normally distributed. A corresponding p-value ≤ 0.05 indicates that the data set is not normally distributed.

### Results

The Kolmogorov–Smirnov test was performed on all Pearson-analyzed data sets to access normality. The age-adjusted AD mortality rates (D = 0.086; \(p\)-value = 0.73), age-adjusted AD prevalence (D = 0.094; \(p\)-value = 0.83), and SCD prevalence (D = 0.107; \(p\)-value = 0.58) data sets were all found to be normally distributed. The CDC oral health survey data sets addressing the percentage of adults who had visited a dentist during the previous year (D = 0.081; \(p\)-value = 0.88), the percentage of adults > age 65 years who had lost all of their teeth (D = 0.121; \(p\)-value = 0.42), and the percentage of adults > age 65 years who had lost ≥ 6 teeth (D = 0.099; \(p\)-value = 0.67) were found to be normally distributed. The U.S. all-stage PdD prevalence (D = 0.095; \(p\)-value = 0.73) and severe-stage PdD prevalence (D = 0.094; \(p\)-value = 0.73) data sets were found to be normally distributed. In summary, all data sets utilized for Pearson correlation coefficient analysis in the present study were found to be normally distributed.

For each state, 2016 CDC oral health survey data addressed the percentage of adults who had visited a dentist during the previous year, the percentage of adults > age 65 years who had lost all of their teeth, and the percentage of adults > age 65 years who had lost ≥ 6 teeth (Table 1, Fig. 1). There were significant negative correlations between the percentage of adults who visited a dentist and age-adjusted AD mortality rates (\(r = -0.50; \ p\)-value = 0.0003), age-adjusted AD prevalence (\(r = -0.30; \ p\)-value = 0.03), and SCD prevalence (\(r = -0.69; \ p\)-value < 0.00001). There were significant positive correlations between the percentage of adults > age 65 years who had lost all of their teeth and age-adjusted AD mortality rate (\(r = 0.55; \ p\)-value = 0.00003), and SCD prevalence (\(r = 0.33; \ p\)-value = 0.018).

Gender-based, age-adjusted AD mortality rate data showed similarly significant correlations with corresponding oral health data regarding percentage of females (\(r = -0.52; \ p\)-value = 0.0001) or males (\(r = -0.42; \ p\)-value = 0.002) visiting a dentist or dental clinic during the previous year, percentage of females (\(r = 0.43; \ p\)-value = 0.001) or males (\(r = 0.37; \ p\)-value = 0.007) > age 65 years who have lost all their teeth, and percentage of females (\(r = 0.36; \ p\)-value = 0.009) or males (\(r = 0.34; \ p\)-value = 0.02) > age 65 years who had lost ≥ 6 teeth (Table 1).

Associations between all-stage PdD prevalence and severe-stage PdD prevalence were compared to age-adjusted AD mortality rate, age-adjusted AD prevalence and SCD prevalence (Table 1 and Fig. 2). No significant correlation was found between age-adjusted AD mortality rate and all-stage PdD prevalence (\(r = 0.08; \ p\)-value = 0.59).

### Table 1. U.S. state-specific age-adjusted AD mortality rates, age-adjusted AD prevalence, SCD prevalence vs. oral health parameters. AD Alzheimer’s disease, SCD Subjective cognitive decline. \(^a\)Periodontal disease. \(^b\)r = Spearman correlation coefficient for ranked data (\(r_s\)).

| Oral Health Data                                | Age-adjusted AD mortality rate (D-value r) | Age-Adjusted AD Prevalence (D-value r) | SCD Prevalence (≥ 45 years D-value r) |
|-------------------------------------------------|------------------------------------------|----------------------------------------|---------------------------------------|
| % visiting dentist, past year                   | \(r = -0.50; \ p\)-value = 0.0003        | \(r = -0.30; \ p\)-value = 0.03         | \(r = -0.69; \ p\)-value < 0.00001    |
| females                                        | \(r = -0.52; \ p\)-value = 0.0001        |                                        |                                       |
| males                                           | \(r = -0.42; \ p\)-value = 0.003         |                                        |                                       |
| % lost all teeth, >65 years                    | \(r = 0.44; \ p\)-value = 0.001          | \(r = 0.46; \ p\)-value = 0.0009        | \(r = 0.37; \ p\)-value = 0.008        |
| females                                        | \(r = 0.43; \ p\)-value = 0.001          |                                        |                                       |
| males                                           | \(r = 0.37; \ p\)-value = 0.007          |                                        |                                       |
| % lost ≥ 6 teeth, >65 years                   | \(r = 0.39; \ p\)-value = 0.005          | \(r = 0.55; \ p\)-value = 0.0003        | \(r = 0.33; \ p\)-value = 0.02         |
| females                                        | \(r = 0.36; \ p\)-value = 0.009          |                                        |                                       |
| males                                           | \(r = 0.34; \ p\)-value = 0.02           |                                        |                                       |
| All-stage PdD\(^a\) prevalence                | \(r = 0.08; \ p\)-value = 0.57           | \(r = 0.38; \ p\)-value = 0.006         | \(r = 0.53; \ p\)-value = 0.0001      |
| Severe-stage PdD prevalence                    | \(r = 0.15; \ p\)-value = 0.30           | \(r = 0.46; \ p\)-value = 0.0009        | \(r = 0.57; \ p\)-value = 0.00002     |
| WalletHub.com oral health overall ranking\(^a\) | \(r = 0.30; \ p\)-value = 0.03           | \(r = 0.38; \ p\)-value = 0.006         | \(r = 0.53; \ p\)-value = 0.00008     |
| Toothbrush.org oral health overall ranking\(^a\)| \(r = 0.35; \ p\)-value = 0.01           | \(r = 0.25; \ p\)-value = 0.08          | \(r = 0.60; \ p\)-value < 0.00001     |
| % Drinking water fluoridation                   | \(r = 0.09; \ p\)-value = 0.55           | \(r = 0.07; \ p\)-value = 0.63          | \(r = -0.01; \ p\)-value = 0.99       |
value = 0.56) or severe PdD prevalence (r = 0.15; p value = 0.30). Significant correlations were found between total PdD prevalence and age-adjusted AD prevalence (r = 0.38; p value = 0.006) and SCD prevalence (r = 0.53; p value = 0.0001). Significant correlations were found between severe PdD prevalence and age-adjusted AD prevalence (r = 0.46; p value = 0.0009) and SCD prevalence (r = 0.57; p value = 0.00002).

WalletHub.com and Toothbrush.org U.S. state oral health rankings were compared to respective age-adjusted AD mortality rate, age-adjusted AD prevalence and SCD prevalence (Table 1, Fig. 3). The WalletHub.

Figure 1. CDC dementia data v CDC oral health metrics. Scatter-plots showing correlations between state-specific age-adjusted AD mortality rates, age-adjusted AD prevalence, SCD prevalence and CDC data regarding state population percent visiting a dentist during the past year, and percentage of adults >65 years who have lost all or ≥6 teeth. Each point represents data from one U.S. state. The Pearson correlation coefficient (r) and corresponding P-value are presented for each correlation. AD Alzheimer’s disease, SCD subjective cognitive decline, CDC Centers for Disease Control and Prevention.
com total oral health rankings were found to be significantly correlated with age-adjusted AD mortality rate ($r = 0.30; p = 0.03$), age-adjusted AD prevalence ($r = 0.38; p = 0.006$) and SCD prevalence ($r = 0.53; p = 0.00008$). The Toothbrush.org total oral health rankings were significantly correlated with age-adjusted AD mortality rate ($r = 0.35; p = 0.01$) and SCD prevalence ($r = 0.60; p < 0.00001$), however, the correlation with age-adjusted AD prevalence ($r = 0.25$) did not reach significance ($p = 0.08$). In order to determine whether these two state-by-state ranking systems were consistent with one another, a Bland Altman analysis was performed and revealed no significant differences ($r = 0; p-value$) between the Toothbrush.org and WalletHub.com state rankings (Fig. 4).

Drinking-water fluoridation, which reduces dental caries but is ineffective against PdD, was utilized as a negative control and examined as a factor associated with AD and SCD (Table 1). No significant correlations were found between the percentage of each state’s population served by fluoridated drinking water and age-adjusted AD mortality rate ($r = 0.09; p = 0.60$), age-adjusted AD prevalence ($r = 0.07; p = 0.63$) or SCD prevalence ($r = -0.003; p = 0.99$) (Table 1). Additionally, no correlations were found between the percentage of each state’s population that is served by fluoridated drinking water and all-stage PdD prevalence ($r = -0.04; p = 0.81$) or severe stage PdD prevalence ($r = 0.005; p = 0.97$), confirming that state water fluoridation rates are unrelated to PdD prevalence.

**Discussion**

Utilizing state-specific, epidemiologic data, we conducted a nationwide correlational analysis examining possible associations between age-adjusted AD mortality rates, age-adjusted AD prevalence, SCD prevalence and oral health metrics relevant to PdD in the U.S. The rationale underlying these comparisons stems from the “antimicrobial protection hypothesis” of AD and recent investigations linking CNS infection, particularly the chronic, recurring infection that is pathognomonic of PdD, with the development and progression of AD.
Figure 3. CDC dementia data vs State oral health ranks. Scatter-plots showing correlations between state-specific age-adjusted AD mortality rates, age-adjusted AD prevalence, SCD prevalence and WalletHub.com and Toothbrush.org state oral health rankings. Each point represents data from one U.S. state. The Spearman correlation coefficient ($r_s$) and corresponding $p$-value are presented for each correlation. AD Alzheimer's disease, SCD subjective cognitive decline, CDC Centers for Disease Control and Prevention.

Figure 4. Bland Altman analysis comparing Toothbrush.org and WalletHub.com oral health ranking systems. No significant differences ($r = 0$, $p$-value = 1.0) were found between the WalletHub.com and Toothbrush.org ranking systems. Dotted lines represent 95% upper (17.56) and lower (−17.56) limits of agreement. Bias = 0, S.D. = ±8.96.
All correlations between CDC oral health data and dementia metrics were statistically significant; however, the strongest association existed between SCD prevalence and the percentage of respondents who visited a dental clinic during the previous year. This finding indicates that regular dental care is associated with a lower SCD prevalence among adults ≥ 45 years; however, it is not clear if the underlying cause of the association is due specifically to a reduction in the severity of PdD. Future research comparing oral health habits and dental health visits among SCD patients diagnosed with PdD versus controls could provide additional information. Given that SCD patients are generally younger than AD patients, establishment of a causative link between SCD and PdD could dramatically impact future medical and economic burdens of AD via policies and programs that address timely, routine dental prophylaxis.

It is known that PdD is the main cause of tooth loss in middle aged and older adults. With regard to tooth loss and edentulous condition among patients older than 65 years, the strongest correlations were observed with age-adjusted AD mortality rates and age-adjusted AD prevalence compared to SCD prevalence. This finding is not unexpected as the AD data comparison reflects a similar age group (i.e.; adults aged 65 + years) compared to the SCD prevalence data (adults ≥ 45 years). These findings are in general agreement with previous studies regarding AD and tooth loss. Stein et al. found that tooth loss due to PdD doubles the risk of onset of AD. A recent meta-analysis performed by Dioguardi et al. reported results with increased rates of partial tooth loss (hazard ratio: 1.52) and complete edentulous condition (hazard ratio: 2.26) amongst AD patients compared to controls. These finding have been supported by other cohort studies. Specifically, the Hisayama study reported correlation between the loss of dental elements and dementia caused specifically by AD, as significant correlations were not found for dementia of vascular origin. Additionally, the simple absence of teeth did not impact Aβ levels or hippocampal pyramidal cells in transgenic AD model mice whose molar teeth were surgically extracted. With regard to gender and tooth loss, we found similar, significant correlations between age-adjusted AD mortality rates and CDC oral health data for both males and females.

State prevalence of any-stage PdD, and severe-stage PdD were found to correlate significantly with both age-adjusted AD prevalence and SCD prevalence. However, no significant associations were found between any-stage or severe-stage PdD prevalence and age-adjusted AD mortality rates. A plausible explanation for this seemingly contradictory finding may be due to confounding effects of P. gingivalis and other PdD pathogen-induced mortality from diseases of organ systems other than the CNS. For example, it has been established that in addition to brain, P. gingivalis can migrate to other systemic sites, such as the cardiovascular system and liver. Several studies have reported the presence of PdD pathogens in coronary atheromatous plaques from myocardial infarction patients and all clinically normal areas of coronary and femoral arterial wall samples from patients with a history cardiovascular disease were found to be colonized by P. gingivalis. Furthermore, viable PdD pathogens have been cultured from atherosclerotic plaques. Clinical and epidemiological studies have demonstrated that PdD contributes to increased mortality from heart failure, ischemic heart disease, peripheral vascular disease, stroke, cancer and pneumonia. All of these conditions are also common in elderly patients afflicted with AD. Therefore, mortality due to myocardial infarction, stroke, cancer or pneumonia in a mildly or moderately affected AD patient would necessitate listing the official "cause of death" as an entity other than AD. This reasoning may help to explain why AD prevalence, but not AD mortality, is correlated with PdD prevalence.

The strongest state-by-state correlations existed between PdD (all-stage or severe-stage) prevalence and SCID prevalence. Because active PdD has been shown to result in continued cognitive decline in AD, aggressive PdD treatment may help to slow or reverse cognitive changes in younger patients with SCD. Once approved, another potential option could include treatment with oral gingipain inhibitors which have been shown to reduce CNS bacterial load, block Aβ production, reduce neuroinflammation, and rescue hippocampal neurons in a tissue culture and mouse model.

Although not specific for PdD, U.S. state rankings from two independent oral health evaluation systems formulated by WalletHub.com and Toothbrush.org were compared to corresponding age-adjusted AD mortality rates, age-adjusted AD prevalence and SCD prevalence. There were significant correlations between WalletHub.com composite state oral health rankings and age-adjusted AD mortality rates, age-adjusted AD prevalence and SCD prevalence. Similarly, significant correlations were found between Toothbrush.org composite state oral health rankings and respective age-adjusted AD mortality rates and SCD prevalence. Given the multi-factorial parameters incorporated into these oral health rating systems, the significance of the associations between state oral health scores and corresponding AD and SCD state epidemiological data is remarkable. Similar state-based ranking scales including factors more specific to PdD-related oral health such as tooth loss, bleeding on probing testing, periodontal pocket depth and degree of gingival recession might be expected to generate even stronger correlations with AD and SCD epidemiological data.

The association between water fluoridation and age-adjusted AD mortality rates, AD prevalence and SCD prevalence was also examined. The addition of fluoride to public water supplies acts to reduce tooth decay and does not impact PdD. The percent of state populations receiving fluoridated water varies across the U.S. We found no correlation between the percent of each state's population served by water fluoridation and corresponding state AD or SCD data. This finding supports the hypothesis that the correlations between oral health metrics and AD data observed in this study are specific to PdD rather than other dental conditions such as caries.

There are limitations of the present study. Due to the disparate nature and sources of the data sets, it was impossible to control for, or adjust for all possible confounding variables, such as economic or educational status, medical comorbidities, ethnicity or age. In certain cases, similarly aged groups were directly compared (e.g.; CDC data regarding edentulism in adults aged 65 + v. AD mortality or prevalence) whereas in other cases, the dataset referred to adults of all-ages (e.g.; CDC data reporting percentage of adults visiting a dentist). Unfortunately, datasets adjusted for all possible confounding variables are simply not available. However, given the levels of significance of our findings, we contend that the adult datasets from high-risk (high mortality and/or prevalence) AD states represent populations that are at greater risk for developing AD or cognitive decline later in life.
Other limitations include the inability to conclusively attribute a clinical causation between PdD and AD, limited sample sizes of cross-sectional datasets relative to state populations, and possible inherent biases of the Toothbrush.org and WalletHub.com oral health rankings. Agreement between the results of the Toothbrush.org and WalletHub.com ranking scales based on Bland Altman analysis obviates some concerns regarding bias of either ranking system. Additionally, CDC data are self-reported and could be biased or inaccurate due to regional differences in survey-response behavioral patterns. However, the sampling of separate cohorts (i.e.: all adults > 65 years and variability of questions (e.g.: dental visits v tooth loss), produced responses that consistently associate AD and SCD with poor oral health. Given these circumstances, it is unlikely that the correlations observed between AD data and CDC oral health data are due solely to regionally-related survey response bias. It is established that PdD is the main etiology underlying tooth loss in middle-aged and elderly adults, however, CDC oral health-related data sets would necessarily include other oral health-related etiologies of tooth loss in addition to PdD72. These conditions include trauma, caries, xerostomia, and chronic enamel erosion. One would expect that inclusion of non-PdD-related conditions would serve to confound, dilute and decrease associations between PdD and AD or SCD. However, despite the inability to exclude PdD-unrelated oral conditions from data sets, strong associations with AD and SCD data were still demonstrated. Additionally, several PdD-associated conditions such as stroke, ischemic heart disease, heart failure and peripheral vascular disease are also frequently encountered in AD patients. The presence or absence of any of these conditions could conceivably confound the results of the present study. Unfortunately, it was not possible to consider these effects as the cross-sectional epidemiological data available for this study did not include information on these comorbid conditions.

In conclusion, significant correlations between state age-adjusted AD mortality, age-adjusted AD prevalence, SCD prevalence and statewide indicators of poor oral health in the U.S were found. Because PdD is a modifiable risk factor, government and private insurance programs or initiatives that positively impact PdD prevalence and severity could substantially reduce the clinical, social and financial burden of AD.

Data availability
All data used available in public domain online. Original spreadsheet for data analysis submitted as supplementary material.

Received: 31 July 2020; Accepted: 17 November 2020
Published online: 01 December 2020

References
1. Kamer, A. R. et al. Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimers Dement. 4(4), 242–250 (2008).
2. Noble, J. M. et al. Serum IgG antibody levels to periodontal microbiota are associated with incident Alzheimer disease. PLoS ONE 9(12), e114959. https://doi.org/10.1371/journal.pone.0114959 (2014).
3. Gaur, S. & Agnihotri, R. Alzheimer's disease and chronic periodontitis: is there an association?. Geriatr. Gerontol. 15(4), 391–404 (2015).
4. Ide, M. et al. Periodontitis and cognitive decline in Alzheimer's disease. PLoS ONE 11(3), e0151081. https://doi.org/10.1371/journal.pone.0151081 (2016).
5. Noble, J. M. et al. Periodontitis is associated with cognitive impairment among older adults: analysis of NHANES-III. J. Neurol. Neurosurg. Psychiatry 80(11), 1206–1211 (2009).
6. Leira, Y. et al. Is periodontal disease associated with Alzheimer's disease? A systematic review with meta-analysis. Neuropsychi- dology 48(1–2), 21–31 (2017).
7. Chen, C. K., Wu, Y. T. & Chang, Y. C. Association between chronic periodontitis and the risk of Alzheimer's disease: a retrospective, population-based, matched-cohort study. Alzheimers Res. Ther. 9(1), 56. https://doi.org/10.1186/s13195-017-0282-6 (2017).
8. Singhrao, S. K. & Olsen, I. Assessing the role of Porphyromonas gingivalis and other periodontal pathogens in determining a causative relationship with Alzheimer's disease. J. Oral Microbiol. 11(1), 1563405. https://doi.org/10.1080/20022297.2018.1563405 (2019).
9. Izhaki, R. F. et al. Microbes and Alzheimer's disease. J. Alzheimers Dis. 51(4), 979–984 (2016).
10. Fulop, T. et al. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer's? Front. Aging Neurosci. 10, 224. https://doi.org/10.3389/fnagi.2018.00224 (2018).
11. Sochocka, M., Zolownicka, K. & Lezerek, J. The infectious etiology of Alzheimer's disease. Curr. Neuropharmacol. 15(7), 996–1009 (2017).
12. Kitazawa, M., Oddo, S., Yamaki, T. R., Green, K. N. & LaFerla, F. M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25(39), 8843–8853 (2005).
13. Lee, D. C. et al. LPS-induced inflammation exacerbates phosphor-tau pathology in rTg4510 mice. J. Neuroinflammation. 7, 56. https://doi.org/10.1186/1742-2094-7-56 (2010).
14. Kumar, A., Singh, A. & Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol. Rep. 67(2), 195–203 (2015).
15. Kostic, D. & Kuesel, I. Deciphering the mechanism underlying late-onset Alzheimer's disease. Nat. Rev. Neurol. 9(1), 25–34 (2013).
16. Noscia, S. J. et al. The Alzheimer’s disease-associated amyloid β-protein is an antimicrobial peptide. PLoS ONE 5(9), e9505. https://doi.org/10.1371/journal.pone.0009505 (2010).
17. Chauhan, A., Ray, I. & Chauhan, V. P. Interaction of amyloid beta-protein with anionic phospholipids: possible involvement of Lys28 and C-terminus aliphatic amino acids. Neurochem. Res. 25(3), 423–429 (2000).
18. Kumar, D. K. et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Sci. Transl. Med. 8(34), 340–372. https://doi.org/10.1126/scitranslmed.aaf1039 (2016).
19. Ilievski, V. et al. Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS ONE 13(10), e0204941. https://doi.org/10.1371/journal.pone.0204941 (2018).
20. Eimer, W. A. et al. Alzheimer's disease-associated beta-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron 99(1), 56–63 (2018).
21. Bourgade, K. et al. Protective effect of amyloid-β peptides against herpes simplex virus-1 infection in a neuronal cell culture model. J. Alzheimers Dis. 50(4), 1227–1241 (2016).
22. White, M. R. et al. Alzheimer's associated b-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS ONE 9(7), e101364. https://doi.org/10.1371/journal.pone.0101364 (2014).
23. Sheng, J. G. et al. Lipopolysaccharide-induced neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. *Neurobiol. Dis.* 14(1), 133–145 (2003).

24. Lee, J. W. et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. *J. Neuroinflammation* 5, 37. https://doi.org/10.1186/1742-2044-5-37 (2008).

25. Dominy, S. S. et al. *Porphyromonas gingivalis* in Alzheimer’s disease brains: evidence for direct causation and treatment with small-molecule inhibitors. *Sci. Adv.* 5(1), 3333. https://doi.org/10.1126/sciadv.aau3333 (2019).

26. Thuret, H. & Pinteaux, E. Microglia in the neurovascular unit: blood-brain barrier-microglia interactions after central nervous system disorders. *Neuroscience* 405, 55–67 (2019).

27. Diaz-Zuniga, J. et al. Serotype b of *Aggregatibacter actinomycetemcomitans* triggers pro-inflammatory responses and amyloid beta secretion in hippocampal cells: a novel link between periodontitis and Alzheimer’s disease. *J. Oral. Microbiol.* 11(1), 1586423. https://doi.org/10.1080/20002297.2019.1586423 (2019).

28. Teixeira, F. B. et al. Periodontitis and Alzheimer’s disease: a possible comorbidity between oral chronic inflammatory condition and neuroinflammation. *Front. Aging Neurosci.* 9, 327. https://doi.org/10.3389/fnagi.2017.00327 (2017).

29. Block, M. L. & Hong, J. S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. *Prog. Neurobiol.* 76(2), 77–98 (2005).

30. Cestari, J. A. et al. Oral infections and cytokine levels in patients with Alzheimer’s disease and mild cognitive impairment compared with controls. *J. Alzheimers Dis.* 52(4), 1479–1485 (2016).

31. Wu, Z. & Nakanishi, H. Connection between periodontitis and Alzheimer’s disease: possible roles of microglia and leptomeningeal cells. *Pharmacol. Sci.* 126(1), 8–13 (2014).

32. Cunningham, C. & Hennessy, E. Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. *Alzheimers Res. Ther.* 7(1), 33. https://doi.org/10.1186/s41395-015-0017-2 (2015).

33. Liu, X., Wu, Z., Hayashi, Y. & Nakanishi, H. Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation. *Neurobiol. Dis.* 32(3), 543–551 (2008).

34. Page, R. C. Kornman KS (1997) The pathogenesis of human periodontitis: an introduction. *Periodontol* 196–203 (2012).

35. Page, R. C. Kornman KS (1997) The pathogenesis of human periodontitis: an introduction. *Periodontol* 196–203 (2012).

36. Herbert, B. A., Novince, C. M. & Kirkwood, K. L. *Porphyromonas gingivalis* is the most abundant species detected in coronary and femoral arteries. *J. Oral Microbiol.* 9(1), 1281562. https://doi.org/10.1007/s40297-019-1281562 (2017).

37. Mougeot, J. C. et al. *Porphyromonas gingivalis* is the most abundant species detected in coronary and femoral arteries. *J. Oral Microbiol.* 9(1), 1281562. https://doi.org/10.1007/s40297-019-1281562 (2017).

38. Reisberg, B., Ferris, S. H., deLeon, M. J. & Crook, T. The global deterioration scale for assessment of primary degenerative dementia. *Neurology* 196–203 (1982).

39. Snitz, B. E. et al. *Porphyromonas gingivalis* outer membrane vesicles microbullets for sporadic Alzheimer's disease manifestations. *J. Alzheimers Dis.* Rep. 4(1), 219–228 (2018).

40. Poole, S., Singhrao, S. K., Kesavalu, L., Curtis, M. A. & Crean, S. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer’s disease brain tissue. *J. Alzheimers Dis.* 36(4), 665–677 (2013).

41. Sparks, Stein, P. et al. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. *Alzheimers Dement.* 8(3), 196–203 (2012).

42. Kamer, A. R. et al. TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer’s disease patients and normal subjects. *J. Neuroimmunol.* 216(1–2), 92–97 (2009).

43. Riviere, G. R., Riviere, K. H. & Smith, K. S. Molecular and immunological evidence of Treponema in the human brain and their association with Alzheimer’s disease. *Oral Microbiol. Immunol.* 17(2), 113–118 (2002).

44. Olsen, I. & Singhrao, S. K. Can oral infection be a risk factor for Alzheimer’s disease?. *J. Oral Microbiol.* 7, 29143. https://doi. 10.3402/om.v7.29143 (2015).

45. Mikloosy, J. Alzheimer’s disease: a neurospirochetosis. Analysis of the evidence following Koch’s and Hill’s criteria. *J. Neuroinflammation* 8, 90. https://doi.org/10.1186/1742-2044-8-90 (2011).

46. Jernsen, F. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. *Alzheimer’s Disease* 10(6), 844–852 (2014).

47. Reisberg, B., Ferris, S. H., deLeon, M. J. & Crook, T. The global deterioration scale for assessment of primary degenerative dementia. *Am. J. Psychiatr.* 139(9), 1136–1139 (1982).

48. Mizuno, A., Ly, M. & Aizenstein, H. I. A homeostatic model of subjective cognitive decline. *Brain Sci.* 8, 12. https://doi.org/10.3390/brainsci8120228 (2018).

49. Mitchell, A. J., Beaumont, H., Ferguson, D., Yadeqarfar, M. & Stubb, B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. *Acta Psychiatr. Scand.* 130(6), 439–451 (2014).

50. Rabin, L. A., Smart, C. M. & Amariglio, R. E. Subjective cognitive decline in preclinical Alzheimer’s disease. *Annu. Rev. Clin. Psychol.* 13, 369–396 (2017).

51. Rodda, J. E., Dammhauer, T. M., Cutinha, D. J., Shergill, S. S. & Walker, Z. Subjective cognitive impairment: increased prefrontal cortex activation compared to controls during an encoding task. *Int. J. Geriatr. Psychiatry* 24(8), 865–874 (2009).

52. Amariglio, R. E. et al. Subjective cognitive complaints and amyloid burden in cognitively normal older adults. *Neuropsychologia* 50(12), 2880–2886 (2012).

53. Ferrotin, A., Mormino, E. C., Madison, C. M., Hayenga, A. O. & Iaqust, W. J. Subjective cognition and amyloid deposition imaging: a Pittsburgh Computed B positron emission tomography study in normal elderly adults. *Arch. Neurol.* 69(2), 223–229 (2012).

54. Goros, B. E. et al. Subjective cognitive complaints, personality and brain amyloid-beta in cognitively normal older adults. *Am. J. Geriatr. Psychiatry* 23(9), 985–993 (2015).

55. Vogel, J. W. et al. Subjective cognitive decline and b-amyloid burden predict cognitive change in healthy elderly. *Neurology* 89(19), 2002–2009 (2017).

56. Martande, S. S. et al. Periodontal health condition in patients with Alzheimer’s disease. *Am. J. Alzheimers Dis. Other Dement.* 29(6), 498–502 (2014).
62. Kim, D. H., Jeong, S. N. & Lee, J. H. Severe periodontitis with tooth loss as a modifiable risk factor for the development of Alzheimer's disease: a systematic review. *J. Periodontal. Implant. Sci.* 50(5), 303–312 (2020).

63. de OliveiraAraujo, R. et al. Association between periodontitis and Alzheimer's disease and its impact on the self-perceived oral health status: a case-control study. *Clin. Oral. Investig.* 5, 2. https://doi.org/10.1007/s00784-020-03489-w (2020).

64. Zhang, S. et al. Poor oral health conditions and cognitive decline: Studies in humans and rats. *PloS ONE* 15(7), e0234659. https://doi.org/10.1371/journal.pone.0234659 (2020).

65. Ryder, M. I. Porphyromonas gingivalis and Alzheimer disease: Recent findings and potential therapies. *J. Periodontal* 91(Suppl 1), S45–S49 (2020).

66. Holmer, J., Eriksdotter, M., Schultzberg, M., Pussinen, P. J. & Buhlin, K. Association between periodontitis and risk of Alzheimer's disease, mild cognitive impairment and subjective cognitive decline: a case-control study. *J. Clin. Periodontol.* 45(11), 1287–1298 (2018).

67. Center for Disease Control and Prevention (CDC) National Center for Health Statistics (2016). https://www.cdc.gov/nchs/pressroom/sosmap/alzheimers_mortality/alzheimers_disease.htm. Accessed 31 Dec 2019.

68. Koller, D. & Bynum, J. P. W. Dementia in the USA: State variation in prevalence. *J. Public Health* 37(4), 597–604 (2015).

69. Taylor, C. A., Bouldin, E. D. & Mcguire, L. C. Subjective cognitive decline among adults aged > 45 years: United States, 2015–2016. *MMWR Morb. Mortal. Wkly. Rep.* 67, 753–757 (2018).

70. Center for Disease Control and Prevention (CDC) Oral health Data 2016 (2016) https://www.cdc.gov/oralhealthdata/. Accessed 18 Dec 2019.

71. Eke, P. I. et al. Predicting periodontitis at state and local levels in the United States. *J. Dent. Res.* 95(5), 515–522 (2016).

72. Office of Disease Prevention and Health Promotion, State-level data (2014) Population served by community water systems with optimally fluoridated water in 2014 (percent). Accessed 18 Dec 2019.

73. McCann A. (2018) States the best & worst dental health. https://wallethub.com/edu/states-with-best-worst-dental-health/31498

74. Toothbrush.org. (2019) Which states have the best oral health in 2019? https://www.toothbrush.org/us-oralhealth/

75. Bishara, A. J. & Hittner, J. B. Testing the significance of a correlation with non-normal data: comparison of Pearson, Spearman, and transformation, and resampling approaches. *Psychol. Method* 17, 399–417 (2012).

76. Klock, K. S. & Haugejorden, O. Primary reasons for extraction of permanent teeth in Norway: changes from 1968 to 1988. *Community Dent. Oral Epidemiol.* 19(6), 336–341 (1991).

77. Kondo, K., Nino, M. & Shido, K. A case-control study of Alzheimer's disease in Japan: significance of lifestyles. *Dementia* 8(6), 314–326 (1994).

78. Stein, P. S., Desrosiers, M., Donegan, S. J., Yepes, J. F. & Kryscio, R. J. Tooth loss, dementia and neuropathology in the nun study. *J Am Dent Assoc* 138(10), 1314–1322 (2007).

79. Dioguardi, M. et al. The association between tooth loss and Alzheimer's disease: a systemic review with meta-analysis of case control studies. *Dent. J.* 7, 2. https://doi.org/10.3390/dj7020049 (2019).

80. Takeuchi, K. et al. Tooth loss and risk of dementia in the community: the Hisayama study. *J. Am. Geriatr. Soc.* 65(5), e95–e100 (2017).

81. Oue, H. et al. Tooth loss might not alter molecular pathogenesis in an aged transgenic Alzheimer's disease model mouse. *Gerodontology* 33(3), 308–314 (2016).

82. Yoshji, C. et al. Detection of periodontal microorganisms in coronary atheromatous plaque specimens of myocardial infarction patients: a systematic review and meta-analysis. *Trends Cardiovasc. Med.* 19, 30175–30176 (2019).

83. Kozarov, E. V., Dorra, B. R., Shellburne, C. E., Dunn, W. A. & Progulske-Fox, A. Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. *Arterioscler. Thromb. Vasc. Biol.* 25(3), e17–18 (2005).

84. Lee, H. U., Choi, E. K., Park, J. B., Han, K. D. & Oh, S. Tooth loss predicts myocardial infarction, heart failure, stroke and death. *J. Dent. Res.* 98(2), 164–170 (2019).

85. Watt, R. G., Tsakos, G., de Oliveira, C. & Hamer, M. Tooth loss and cardiovascular disease mortality risk: results from the Scottish Health Survey. *PloS ONE* 7(2), e30797. https://doi.org/10.1371/journal.pone.0307979 (2012).

86. Janket, S. J., Baird, A. E., Chuang, S. K. & Jones, J. A. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* 95(5), 559–569 (2003).

87. Bahakar, A. A., Singh, S., Saha, S., Molnar, J. & Arora, R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. *Am. Heart J.* 154(3), 836–837 (2007).

88. Humphrey, J. L., Fu, R., Buckley, D. I., Freeman, M. & Halfand, M. Periodontal disease and coronary heart disease incidence: a systemic review and meta-analysis. *J. Gen. Intern. Med.* 23(12), 2079–2086 (2008).

89. Wu, T. et al. Periodontal disease and risk of cerebrovascular disease: the first national healthand nutrition examination survey and its follow-up study. *Arch. Inten. Med.* 160(18), 2749–2755 (2000).

90. Joshy, G., Arora, M., Korda, R. J., Chalmers, J. & Banks, E. Is poor oral health a risk marker for incident cardiovascular disease hospitalization and all-cause mortality? Findings from 172630 participants from the prospective 45 and Up Study. *BMJ Open* 6(8), e012386. https://doi.org/10.1136/bmjopen-2016-012386 (2016).

91. Jansson, L., Kalkali, H. & Mulk Niazi, F. Mortality rate and oral health: a cohort study over 44 years in the county of Stockholm. *Acta Odont. Scand.* 76(4), 299–304 (2018).

92. Iwasaki, M. et al. Periodontal disease and pneumonia mortality in haemodialysis patients: a 7-year cohort study. *J. Clin. Periodontol.* 41(3), 38–45 (2018).

93. Centers for Disease Control and Prevention. Recommendations for using fluoride to prevent and control dental caries in the United States. *MMWR Recomm Rec* 50(14), 1–42 (2001).

Acknowledgements

We would like to thank Susan B. Udin, Ph.D., Professor, Dept. of Physiology, University at Buffalo, Buffalo, NY, for her help in editing the manuscript.

Author contributions

W.J.S.: Study concept, data collection and analysis, writing, design of figures and tables. R.X.S.: Study concept, data collection, writing, statistical analysis.

Competing interests

The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-77937-8.

Correspondence and requests for materials should be addressed to W.J.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020